ChemoCentryx’s Tavneos Approved in Japan for MPA, GPA

ChemoCentryx’s Tavneos Approved in Japan for MPA, GPA

307578

ChemoCentryx’s Tavneos Approved in Japan for MPA, GPA

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Tavneos (avacopan) for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). The approval of this first-in-class therapy — for the two main forms of ANCA-associated vasculitis (AAV) — was granted to Kissei Pharmaceuticals, which owns an exclusive license from Vifor Pharma to develop and commercialize the therapy in Japan. Tavneos’ development and commercial rights in the U.S. are owned by ChemoCentryx, the…

You must be logged in to read/download the full post.